Evidence map›Paper›PMID 34452396›Full record

ArticleViruses2021

NIgPred: Class-Specific Antibody Prediction for Linear B-Cell Epitopes Based on Heterogeneous Features and Machine-Learning Approaches.

Chi-Hua Tung, Yi-Sheng Chang, Kai-Po Chang, Yen-Wei Chu

Abstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Multi-perspectives and challenges in identifying B-cell epitopes.Protein science : a publication of the Protein Society · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chi-Hua TungDepartment of Bioinformatics, Chung Hua University, Hsinchu City 300, Taiwan.ORCID 0000-0002-7232-312X
Yi-Sheng ChangInstitute of Genomics and Bioinformatics, National Chung Hsing University, 145 Xingda Rd., South Dist., Taichung City 402, Taiwan.
Kai-Po ChangPh.D. Program in Medical Biotechnology, National Chung Hsing University, 145 Xingda Rd., South Dist., Taichung City 402, Taiwan.
Yen-Wei ChuInstitute of Genomics and Bioinformatics, National Chung Hsing University, 145 Xingda Rd., South Dist., Taichung City 402, Taiwan.ORCID 0000-0002-5525-4011

Funding

China Medical University Hospital DMR-109-258Ministry of Science and Technology, Taiwan 109-2320-B-039-005Ministry of Science and Technology, Taiwan 109-2321-B-005-024National Chung Hsing University and Changhua Christian Hospital NCHU-CCH 11006National Chung Hsing University and Chung-Shan Medical University NCHU-CSMU 10911Taichung Veterans General Hospital and National Chung Hsing University TCVGH-NCHU-1097618
6 · The paper itself

Abstract

Upon invasion by foreign pathogens, specific antibodies can identify specific foreign antigens and disable them. As a result of this ability, antibodies can help with vaccine production and food allergen detection in patients. Many studies have focused on predicting linear B-cell epitopes, but only two prediction tools are currently available to predict the sub-type of an epitope. NIgPred was developed as a prediction tool for IgA, IgE, and IgG. NIgPred integrates various heterologous features with machine-learning approaches. Differently from previous studies, our study considered peptide-characteristic correlation and autocorrelation features. Sixty kinds of classifier were applied to construct the best prediction model. Furthermore, the genetic algorithm and hill-climbing algorithm were used to select the most suitable features for improving the accuracy and reducing the time complexity of the training model. NIgPred was found to be superior to the currently available tools for predicting IgE epitopes and IgG epitopes on independent test sets. Moreover, NIgPred achieved a prediction accuracy of 100% for the IgG epitopes of a coronavirus data set. NIgPred is publicly available at our website.

Indexed as

Machine LearningAlgorithmsCoronavirus Envelope ProteinsCoronavirus M ProteinsCoronavirus Nucleocapsid ProteinsCOVID-19Epitopes, B-LymphocyteHumansImmunoglobulin AImmunoglobulin EImmunoglobulin GPhosphoproteinsSARS-CoV-2SoftwareSpike Glycoprotein, CoronavirusViral Matrix ProteinsCoronavirus Envelope ProteinsCoronavirus M ProteinsCoronavirus Nucleocapsid Proteinsenvelope protein, SARS-CoV-2Epitopes, B-LymphocyteImmunoglobulin AImmunoglobulin EImmunoglobulin Gmembrane protein, SARS-CoV-2nucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Matrix ProteinsantibodyantigenB-cell epitopefeature selectionmachine learning

Identifiers

PMID34452396
PMCPMC8402714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.